|
Alterations of DNA damage response (DDR) genes correlate with favorable response and overall survival (OS) in anti-PD-1/PD-L1-treated advanced urothelial cancer (UC). |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Merck; Pfizer; QED Therapeutics; Seagen |
Speakers' Bureau - Bristol-Myers Squibb; Genentech |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst) |
| |
|
Honoraria - Motive Medical Intelligence |
Consulting or Advisory Role - Genentech/Roche |
Research Funding - Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst) |
| |
|
Consulting or Advisory Role - Bayer; Lilly |
Speakers' Bureau - Dendreon; Sanofi |
Research Funding - Prometheus |
Travel, Accommodations, Expenses - Lilly |
| |
|
No Relationships to Disclose |
| |
|
Employment - Foundation Medicine |
Patents, Royalties, Other Intellectual Property - My husband receives royalty distributions for licensing the TRPA1 mouse model through Harvard University and Howard Hughes Medical Institute. (I) |
Travel, Accommodations, Expenses - Foundation Medicine |
| |
|
Employment - Hope Healthcare |
Consulting or Advisory Role - Valeant/Dendreon |
Travel, Accommodations, Expenses - Valeant/Dendreon |
| |
|
Consulting or Advisory Role - Castle Biosciences |
| |
|
No Relationships to Disclose |